Meeting
2024 ASCO Gastrointestinal Cancers Symposium
De-escalation and dose density in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line.
Authors
Syvart Dennen
Genesis Research, Hoboken, NJ
Syvart Dennen , Anran Shao , Syvart Dennen , Paul Cockrum , Ravi Kumar Paluri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 628)
DOI
10.1200/JCO.2024.42.3_suppl.628
Abstract #
628
Poster Bd #
J15
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Activity and safety of Nab-FOLFIRI and Nab-FOLFOX as first-line treatment for metastatic pancreatic cancer (phase II NabucCO study).
First Author: Elisa Giommoni
Poster
2023 ASCO Annual Meeting
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).
First Author: Haeseong Park
Poster
2021 ASCO Annual Meeting
Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) as first-line treatment for de novo metastatic pancreatic cancer (MPC): Safety and effect.
First Author: Brett A. Schroeder
Poster
2021 ASCO Annual Meeting
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.
First Author: Nai-Jung Chiang